This report describes results from our analysis of the activity and biodistribution of a novel pan-ERBB inhibitor, NT113, when used in treating mice with intracranial glioblastoma (GBM) xenografts. Approaches used in this investigation include: bioluminescence imaging (BLI) for monitoring intracranial tumor growth and response to therapy; determination of survival benefit from treatment; analysis of tumor immunohistochemical (IHC) reactivity for indication of treatment effect on proliferation and apoptotic response; western blot for determination of effects of treatment on ERBB and ERBB signaling mediator activation; and high performance liquid chromatography for determination of NT113 concentration in tissue extracts from animals receiving oral administration of inhibitor. Our results show that NT113 is active against GBM xenografts in which wild-type EGFR or EGFRvIII is highly expressed. In experiments including lapatinib and/or erlotinib, NT113 treatment was associated with the most substantial improvement in survival, as well as the most substantial tumor growth inhibition, as indicated by BLI and IHC results. Western blot results indicated that NT113 has inhibitory activity, both in vivo and in vitro, on ERBB family member phosphorylation, as well as on the phosphorylation of downstream signaling mediator Akt. Results from the analysis of animal tissues revealed significantly higher NT113 normal brain-to-plasma and intracranial tumor-to-plasma ratios for NT113, relative to erlotinib, indicating superior NT113 partitioning to intracranial tissue compartments. These data provide a strong rationale for the clinical investigation of NT113, a novel ERBB inhibitor, in treating patients with GBM.
Introduction
ERBB family tyrosine kinases, especially epidermal growth factor receptor (EGFR), continue to attract substantial attention as therapeutic targets for treating various forms of cancer, including glioblastoma (GBM), the most common and malignant form of primary brain tumor in adults (1) .
EGFR is amplified and/or rearranged in up to 40% of GBM (2) (3) (4) , and as a result it is widely considered a key oncogenic driver of the aggressive biological behavior of a sizeable subgroup of GBM.
First generation EGFR inhibitors erlotinib and gefitinib, as well as dual EGFR + ERBB2/HER2
inhibitor lapatinib, have been used, and continue to see use, in clinical neuro-oncology, despite widespread appreciation of their shortcomings, which include limited central nervous system penetration (5-7), conformational limiting effects of GBM-specific mutant EGFR on inhibitor activity (8) , and GBM adaptation to EGFR inhibition through activation of alternative receptor tyrosine kinases (9, 10) . Contemporary clinical trials for treating GBM patients with EGFRdirected therapeutics are seeking to enrich for responders by using patient tumor EGFR status as a clinical trial inclusion/exclusion criterion (http://clinicaltrials.gov/show/NCT01475006).
Despite the use of responder enrichment strategies, there has yet to be clear indication of consistent and/or substantial benefit from the use of EGFR targeted therapies, as single agents, in treating patients with GBM (11, 12) . More recently, preclinical and clinical investigations of ERBB inhibitors for treating GBM have shifted focus to combination therapy approaches that are intended to address resistance mechanisms to EGFR-directed monotherapy (13, 14) .
An additional concept that is currently being investigated for exploiting EGFR as a therapeutic target in cancer, including GBM, involves the use of second generation irreversible ERBB and EGFR inhibitors (15) . A concern for the use of such inhibitors, especially the pan inhibitors that act against multiple ERBB family members, is achieving a therapeutic window necessary for 4 maximizing anti-tumor activity, while minimizing adverse events. A trial of Afatinib in recurrent GBM may have been negative for these reasons (16) .
In the current study we have conducted preclinical analysis of a novel irreversible pan-ERBB inhibitor, NT113, for activity against orthotopic GBM xenografts. Our interest in testing this therapeutic stems from its preferential partitioning in brain, combined with favorable in vivo stability (17) . Our results indicate high-level expression of wild-type or vIII mutant EGFR as identifying NT113 responsive-GBM, using an NT113 administration regimen that is well tolerated and without indication of adverse events in animal subjects. In aggregate, our results support NT113 clinical investigation in patients with GBM whose tumors express high levels of EGFR, a molecular characteristic that is invariably associated with corresponding gene amplification (2-4). 
Materials and Methods

Investigational agent
NT113 is a quinazolinyl acrylamide based pan-ERBB irreversible inhibitor, and was provided by NewGen Therapeutics (Menlo Park, CA). For oral administration to animal subjects, NT113, as well as erlotinib and lapatinib (LC Laboratories, Woburn, MA), were dissolved in 2% N,NDimethylacetamide and 40% 2-Hydroxypropyl-beta-cyclodextrin at concentrations of 10, 100, and 150 mg/ml, respectively. For addition to cell cultures, stock solutions of NT113 and erlotinib were prepared by dissolution in dimethylsulfoxide (DMSO) at 10 mM.
GBM Cell Sources
The U87 cell line was obtained from ATCC (catalogue identifier HTB14). U87 modification by retroviral introduction of EGFRvIII, in developing the derivative cell line U87vIII, has been described (18) . Human GBM tissues, GBM6, GBM12, and GBM39, are maintained as serially passaged subcutaneous xenografts in athymic mice (19) . Information regarding the EGFR status of these xenografts, and available clinical characteristics of the patients from which they were derived, have been previously described (20) . Each of these, as well as the U87 and U87vIII cell lines, has been modified by lentiviral infection for stable expression of firefly luciferase to enable in vivo bioluminescence imaging (21) . The procedure for the preparation of tumor cells from subcutaneous xenografts for transfer to the intracranial compartment, has been previously described (22, 23) .
All cell sources used here were verified through DNA fingerprinting using the Promega Powerplex platform. reagent (Roche) was added, and sample 450 nm absorbance determined using a microplate reader (Gen5, BioTek), with background reading at 800 nm subtracted.
Western blot analysis
Cells were serum starved overnight before being treated with 1 PM EGFR inhibitor for two hours followed by 5 nM EGF stimulation for 10 min. Cells and tissues were lysed in buffer (Cell Signaling) supplemented with proteinase (Roche) and phosphatase (Sigma) inhibitor cocktails.
Proteins in lysates were separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes. After probing with primary antibodies, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody, and visualized by ECL (Pierce).
Antibodies specific for total and phospho EGFR, ERBB2, ERBB4, Akt, ERK and beta-actin were obtained from Cell Signaling.
Intracranial Tumor Establishment in Athymic Mice
Five-week-old female athymic mice (nu/nu, homozygous; Simonsen Laboratories, Gilroy, CA), housed under aseptic conditions, received intracranial tumor cell injection, as approved by the University of California San Francisco Institutional Animal Care and Use Committee. In brief, mice were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg), and then were injected with 3 PL of tumor cell suspension (300,000 cells total) into the right caudate putamen (22, 23) .
Bioluminescence Monitoring of Intracranial Tumor Growth
In preparation for bioluminescence imaging (BLI), mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 
Immunohistochemistry
Resected mouse brains were fixed in 10% buffered formalin, then paraffin-embedded and sectioned for hematoxylin and eosin (H&E) staining and immunohistochemical (IHC) analysis.
To determine cleaved caspase-3 reactivity, unstained sections were processed with a Ventana BenchMark XT automated system and a protocol consisting of pretreatment with 3% ethanolic hydrogen peroxide for 32 min at room temperature, epitope retrieval in Tris buffer ( 
Biodistribution Studies
Mice with intracranial GBM12 tumors were administered NT113, at 10 mg/kg/day for 3 days, with blood and intracranial tissue samples obtained 2 hours following the third administration.
Plasma was separated from whole blood, and frozen at -80 o C. After brain resection, tumor tissue was immediately dissected from tumor-bearing hemisphere, then snap frozen and stored at -80 o C, as was contralateral hemisphere without tumor. NT113 was extracted from homogenized tissues using a Bullet Blender (Next Advance, Inc., New York, NY).
Homogenates were extracted with organic solvent and further processed prior to transfer to an autosampler for high performance liquid chromatography (HPLC) analysis (Shimadzu VP Series 10 System), and determination of NT113 content (Integrated Analytical Systems, Berkeley, CA). 
Statistical Analysis
Results
NT113 in vivo anti-tumor activity
Our initial experiment with NT113 ( Supplementary Figure 1) , which shows specificity for inhibiting EGFR, including EGFR kinase domain mutants that are common in lung cancer (24) , ERBB2, and ERBB4 (Supplementary Table 1) , utilized an EGFRvIII amplified cell source, GBM39, which we have previously shown to be highly responsive to erlotinib treatment (25) .
Results from BLI suggested a complete arrest of GBM39 intracranial growth during a 2-week period of NT113 treatment ( Figure 1A , 1B), at 20 mg/kg/day, and a corresponding significant survival benefit ( Figure 1C ). Body weight monitoring of animal subjects revealed an initial decrease in weight associated with NT113 administration ( Figure 1D ), which stabilized at day 4 of treatment, and remained stable until treatment was completed, at which time NT113-treated animals showed rapid weight gain. Mild skin rash was also observed in some NT113 treated animals while on therapy, but resolved quickly upon therapy completion (data not shown).
Because of the observation of skin rash combined with body weight decrease of animal subjects, we investigated lower daily dose administrations of NT113, so that in subsequent experiments animal subjects could receive continuous daily administration of NT113, without periodic interruption, and without indication of adverse effects. This analysis revealed that a 10 mg/kg daily administration was well tolerated by athymic mice for up to 28 consecutive days.
Similar analyses were conducted for erlotinib and the dual ERBB inhibitor lapatinib, which revealed that 100 mg/kg/day and 150 mg/kg b.i.d., respectively, were well tolerated by animal subjects, over extended periods of time.
Effect of EGFRvIII expression on NT113 activity
Amplification and overexpression of EGFRvIII has previously been associated with GBM response to EGFR inhibition (25, 26) . To address the importance of EGFRvIII expression for intracranial GBM xenograft response to NT113 treatment, we used the isogenic cell pair U87- Figure 2A) , showed detectable p-EGFRvIII, p-ERBB2, p-ERBB4, and p-Akt, the levels for all of which were reduced as a result of NT113 treatment ( Figure 3 ). Erlotinib treatment of U87vIII cells also inhibited EGFRvIII, ERBB2, and Akt phosphorylation, though to a lesser extent than observed with NT113. Moreover, and in contrast to NT113, erlotinib did not inhibit ERBB4 phosphorylation.
NT113, erlotinib, and lapatinib in vivo comparison
GBM12 intracranial tumors, which have amplified wild-type EGFR (19) , and that we previously found as being responsive to erlotinib treatment (25) , though less so than GBM39, were next Mice receiving intracranial injection with GBM12 were also used to compare the efficacy of NT113 vs. that of erlotinib, but with treatments initiated on day 23-post tumor cell implantation.
As for the previous comparison, BLI results revealed that each inhibitor delayed tumor growth, to a significant extent, with the growth delay from NT113 significantly more than from erlotinib ( Figure 5A ). Survival results were again consistent with BLI in showing significant survival benefit from treatment with either inhibitor, and that survival benefit from NT113 was significantly greater than from erlotinib (p = 0.047: Figure 5B ).
Analysis of NT113 anti-tumor activities and biodistribution
Mice with intracranial GBM12 were additionally used for analysis of inhibitor signaling mediator effects, in vivo, and for analysis of inhibitor biodistribution. With respect to the former, one mouse from the NT113 and erlotinib treatment groups were euthanized following one week of therapy, with fresh tumor tissue dissected from resected brain, and dissected tumor used for obtaining protein extracts for western blot analysis. Included in this analysis was a protein extract from intracranial GBM12 obtained from a mouse following one week of lapatinib treatment. Results for EGFR phosphorylation indicated NT113 as having the most substantial 
inhibitory effect, whereas NT113 and erlotinib had similar inhibitory effect on Akt phosphorylation ( Figure 5C ). Little phosphorylation effect was evident from lapatinib treatment, despite indication of lapatinib anti-proliferative effect against intracranial GBM12, as well as survival benefit for mice receiving lapatinib treatment (Figure 4 ).
To assess brain and tumor biodistribution, four mice each from the NT113 and erlotinib treatment groups were euthanized at 2 hours following their third treatment with inhibitor. Blood was drawn from each mouse immediately prior to euthanasia, and following euthanasia brains were immediately resected, with tumor tissue dissected, and contralateral brain, without tumor, separated for obtaining tissue extracts to subject to HPLC analysis for inhibitor content. Results from the HPLC analysis (Supplementary Table 2 ) showed significantly greater tumor-to-plasma and normal brain-to-plasma content for NT113, thereby indicating superior partitioning of NT113 to normal brain as well as to intracranial tumor ( Figures 5D, 5E ). Moreover, in 4 of 4 mice, intracranial tumor NT113 concentration was greater than for corresponding contralateral brain (mean tumor-to-normal brain = 10.5: Figure 5F ), indicating preferential NT113 sequestration in tumor.
With erlotinib doses 10x greater than for NT113 (100 mg/kg/day vs. 10 mg/kg/day), it was not necessarily unexpected that the average amount of erlotinib in intracranial tumor tissue was greater than the average amount for NT113 (330 vs. 157 mg/kg: Supplementary Table 2) . Consequently, the heightened inhibitory effect of NT113 on EGFR phosphorylation ( Figure 5C) is presumably not attributable to a reduced amount of erlotinib, relative to NT113, reaching intracranial tumor.
Generalization of NT113 activity to EGFR-amplified GBM
In our previous analysis of GBM xenografts for response to erlotinib, we concluded that tumor EGFR amplification and maintenance of wild-type PTEN expression were necessary but not 
sufficient for identifying GBM that should be erlotinib sensitive (25) . An example of a GBM xenograft with appropriate molecular characteristics for anticipating sensitivity, but that proved to be non-responsive to erlotinib, is GBM6, which has amplified EGFRvIII and expresses wildtype PTEN. To address the possibility of NT113 having broader spectrum activity against GBM than erlotinib, we conducted an additional therapy-response experiment, using mice that had received intracranial injection with GBM6, and then treated with either NT113 or erlotinib. BLI results obtained on day 16-post tumor cell injection, and following 5 days of treatment, showed no significant anti-tumor effect from erlotinib, whereas 5 days of treatment with NT113 had significantly slowed tumor growth, both in relation to control mice, as well as with respect to mice receiving erlotinib treatment ( Figure 6A) . Imaging results at day 20-post tumor cell implantation and following day 9 of treatment confirmed a significant difference in bioluminescence for NT113 and erlotinib treatment groups ( Figure 6B ). Consistent with our previous results for erlotinib treatment of mice with intracranial GBM6, there was no indication of survival benefit from administration of this EGFR inhibitor, whereas mice receiving NT113 survived significantly longer than mice receiving no treatment, or mice receiving treatment with erlotinib (p < 0.001 for NT113 vs. erlotinib comparison: Figure 6C) . Importantly, immunoblot analysis of GBM6 total protein, as well as total protein for GBM39 and GBM12, revealed readily detectable ERBB2 in GBM6 only (Supplementary Figure 2B) . 
Discussion
The results presented highlight several points of interest regarding NT113. First, they indicate a broader spectrum of GBM as being responsive to NT113 than erlotinib, which has seen extensive, and predominantly negative clinical trial evaluation for improving outcomes of GBM patients. Examples in support of NT113 being active against a larger fraction of GBM include the results from the GBM6 and U87vIII intracranial xenograft models. GBM6, though of appropriate genotype for anticipating sensitivity to EGFR small molecule inhibition, is not responsive to erlotinib, but shows distinct growth suppression from NT113 treatment, and mice with intracranial GBM6 experience significant survival benefit from treatment with NT113 ( Figure   6 ). U87 and its EGFRvIII derivative are PTEN deficient, and intracranial U87vIII shows suppressed growth from treatment with NT113 ( Figure 2C ). In our previous study testing GBM intracranial xenograft response to erlotinib (25), we concluded that tumor maintenance of wildtype PTEN expression is a GBM molecular characteristic that may be required for tumor response to this inhibitor, which is an interpretation that is consistent with clinical trial results
(26).
Three of the five xenograft models used in our study involve cell sources that highly express EGFRvIII, and their collective results strongly implicate EGFRvIII, in and of itself, as a biomarker predictive of GBM response to NT113 treatment. This relationship is perhaps most strongly supported by the comparison of parental U87 vs. derivative U87vIII xenograft response to NT113 treatment (Figure 2 ). An alternative approach, involving the use of isogenic cell pairs for testing the importance of EGFRvIII to NT113 response, would be to develop derivatives of GBM6 or GBM39 cells, in which shRNA expression was used to suppress endogenous EGFRvIII expression, and determine whether NT113 responsiveness was diminished in association with suppression of EGFRvIII expression. In addition to the EGFRvIII-NT113 response relationship, results from our use of the GBM12 model, with amplified wild-type EGFR and positive for expression of wild-type PTEN (19, 25) , showed this tumor as being responsive to NT113. The unmodified, parental U87 model, with low-level endogenous EGFR expression ( Supplementary Figure 2A) , was the only type of GBM xenograft tested that failed to show response to NT113 treatment. Collectively, our results indicate that patients whose tumors have amplified wild-type EGFR and/or amplified EGFRvIII, which invariably result in elevated expression of encoded protein (2) (3) (4) 27) , are candidates for benefiting from NT113 treatment.
As well as being an irreversible ERBB inhibitor, as based on chemical structure homology comparisons, the pan-ERBB inhibitory activity of NT113 (EGFR, ERBB2, and ERBB4 shown here: Figure 3 Figure 2B) , combined with the distinct response of intracranial GBM6 to NT113 vs. erlotinib, suggests that the pan-selectivity of NT113 (see U87vIII results in Figure 3 ) is a key contributor to its efficacy against tumors that express multiple ERBB family members. In addition to the impact of ERBB family members, other than EGFR, the activities of non-ERBB receptor tyrosine kinases, as determinants of GBM response and resistance to EGFR therapeutic targeting, are thought to be of importance (9, 10) . Table 2 ), suggesting that, at this time, that GBM12 tumor is experiencing a higher concentration of erlotinib than NT113, though responding less to the erlotinib regimen than to the NT113 regimen. Additional NT113 pharmacokinetic results, from a multi-timepoint analysis of NT113 concentration in plasma, from rats receiving oral administration of NT113 at 5 mg/kg, indicate maximal NT113 plasma concentration is achieved by 4 hrs post oral administration, and that at least 77% this maximal level is maintained between hrs 1-8, p.o. (Supplementary Figure 4) . This, in combination with the IC50 and tumor-to-plasma partitioning results (Supplementary Figure 3 and Figure 5D , respectively), support that an antiproliferative concentration of NT113 is reached and sustained in intracranial tumor for several hours following oral administration of 10 mg/kg NT113. Although not tested, we expect that U87vIII intracranial xenograft tumors would have even higher concentration of NT113 than GBM12 tumors because of the circumscribed nature of U87vIII intracranial xenografts, the growth of which is more disruptive of the blood-brain barrier than GBM12 intracranial tumors, which grow in an infiltrative manner, as is also the case for GBM6 intracranial xenografts (22) .
Pro-apoptotic activity of pan-ERBB inhibitors, in preclinical studies, has been previously noted (28, 29) , and was evident for NT113-intracranial GBM xenografts, as indicated by increased activated caspase 3 staining ( Figure 4D ). Therefore, NT113 acts to slow tumor growth through combined anti-proliferative and pro-apoptotic effects. 
As noted, a major concern for ERBB inhibitors as monotherapies for treating cancer, including GBM, is tumor adaptation through various mechanisms, including activation of compensating receptor tyrosine kinases (9, 10) . Indeed, comparison of bioluminescence growth curves for two of the tumor models used here indicate complete stasis for GBM39 (Figure 1A) , during the two week course of treatment, whereas GBM12 intracranial tumors, subjected to continuous daily administration of NT113, appear to begin growing after 2-3 weeks of treatment ( Figures 4A, 5A ).
Whereas GBM adaptation to any monotherapy is to be expected, the variability and duration of tumor responsiveness to NT113 are yet to be determined, as are GBM adaptive mechanisms to sustained NT113 treatment. Further investigation will resolve these important issues, as will studies aimed at identifying optimal therapeutic partners for combination treatments with NT113. 
